BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|October 11, 2010
- Volume 0 0
TEST TITLE
Author(s)TEST
Advertisement
TEST
Articles in this issue
over 18 years ago
Gout: A Big Pain in the Big Toeover 18 years ago
can you READ these Rxs?over 18 years ago
Case Studiesover 18 years ago
ASTHMA WATCHover 18 years ago
CHOLESTEROL WATCHover 18 years ago
ARTHRITIS WATCHover 18 years ago
DIABETES WATCHover 18 years ago
WOMEN'S HEALTH WATCHover 18 years ago
pharmacy TECHNOLOGY productsover 18 years ago
compounding HOTLINEAdvertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement